US › Healthcare

Rocket Pharmaceuticals Inc (RCKT)

US · Healthcare · Biotechnology

$3.44+0.88%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-47.6M
Profit YoY
+22.4%
EPS
$-0.42
EPS estimate
$-0.45

EPS came in at -0.42 against a street estimate of -0.45 — a beat of 6.7%.

Key statistics

Market cap
$372.4M
Forward P/E
0.0
P/B
1.43
Book value
$2.18
EPS (TTM)
$-1.87
52-week high
$5.45
52-week low
$2.53
50-day MA
$3.25
200-day MA
$3.58
Beta
0.47

Analyst view

Analysts rate Rocket Pharmaceuticals Inc a strong buy (17 buy, 1 hold, 0 sell out of 18) with an average price target of $9.39.

Shareholding

Insiders
3.10%
Institutions
89.46%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC16.20%
Vanguard Group Inc7.83%
BlackRock Inc7.18%
Citigroup Inc4.68%
Vanguard Portfolio Management, LLC4.30%
State Street Corp4.11%
Vanguard Capital Management, LLC3.46%
Maverick Capital Ltd3.27%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rocket Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.